Our goal was to investigate whether early follicular supplementation of the GnRH antagonist to the flexible GnRH antagonist protocol, has a potential to improve IVF-ET clinical results
GnRH antagonist offers many advantages when used in IVF-ET treatment, however, it is suspected to yield lower pregnancy rate when compared with the long GnRH agonist protocol. Our goal was to investigate whether early follicular supplementation of the GnRH antagonist to the flexible GnRH antagonist protocol, has a potential to improve IVF-ET clinical results. Consecutive patients are prospectively enrolled and randomly assigned to the study and control groups. Patients with low ovarian reserve or with uterine distortion are excluded from the study. Both groups are treated with recombinant FSH and the flexible GnRH antagonist protocol. Women in the study group are also treated with additional GnRH antagonist 0.25 mg/day on day 1, 2 and 3 of the menstrual cycle.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
50
sc injection of Ganirelix 0.25 mg per day
The Baruch Padeh medical center, Poriya
Tiberias, Israel
pregnancy rates
Time frame: one cycle
differences in hormonal levels
Time frame: one cycle
differences in the basic treatment doses
Time frame: one cycle
oocyte counts
Time frame: one cycle
fertilization rate
Time frame: one cycle
cleavage rate
Time frame: one cycle
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.